Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease
Flagship Pioneering has announced a new collaboration between its drug discovery unit Pioneering Medicines and Pfizer to discover potential novel inhibitors for autoimmune disease treatment. The partnership will utilize Logica, a platform developed by Valo Health and Charles River that combines AI-powered technology with drug discovery expertise to translate biological insights into optimized small molecules.
This marks the sixth agreement under the strategic partnership between Flagship Pioneering and Pfizer, following previous collaborations with ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics, and Ampersand Biomedicines. The initiative aims to address the unmet needs in autoimmune disease management by developing more effective, safer, and personalized treatment options.
Flagship Pioneering ha annunciato una nuova collaborazione tra la sua unità di scoperta di farmaci Pioneering Medicines e Pfizer per scoprire potenziali nuovi inibitori per il trattamento delle malattie autoimmuni. La partnership utilizzerà Logica, una piattaforma sviluppata da Valo Health e Charles River che combina tecnologia basata sull'IA con competenze nella scoperta di farmaci per tradurre intuizioni biologiche in piccole molecole ottimizzate.
Questo segna il sesto accordo nell'ambito della partnership strategica tra Flagship Pioneering e Pfizer, dopo precedenti collaborazioni con ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics e Ampersand Biomedicines. L'iniziativa mira a soddisfare le esigenze insoddisfatte nella gestione delle malattie autoimmuni sviluppando opzioni di trattamento più efficaci, sicure e personalizzate.
Flagship Pioneering ha anunciado una nueva colaboración entre su unidad de descubrimiento de fármacos Pioneering Medicines y Pfizer para descubrir posibles nuevos inhibidores para el tratamiento de enfermedades autoinmunes. La asociación utilizará Logica, una plataforma desarrollada por Valo Health y Charles River que combina tecnología impulsada por IA con experiencia en descubrimiento de fármacos para traducir conocimientos biológicos en pequeñas moléculas optimizadas.
Esto marca el sexto acuerdo bajo la asociación estratégica entre Flagship Pioneering y Pfizer, después de colaboraciones anteriores con ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics y Ampersand Biomedicines. La iniciativa tiene como objetivo abordar las necesidades no satisfechas en el manejo de enfermedades autoinmunes mediante el desarrollo de opciones de tratamiento más efectivas, seguras y personalizadas.
Flagship Pioneering는 자사의 약물 발견 부서 Pioneering Medicines와 Pfizer 간의 새로운 협력 관계를 발표하며 자가면역 질환 치료를 위한 잠재적 신규 억제제를 발견할 예정이다. 이 파트너십은 Valo Health와 Charles River가 개발한 플랫폼 Logica를 활용하여 AI 기반 기술과 약물 발견 전문성을 결합하여 생물학적 통찰력을 최적화된 소분자로 변환할 것이다.
이는 Flagship Pioneering과 Pfizer 간의 전략적 파트너십에 따른 여섯 번째 계약으로, ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics 및 Ampersand Biomedicines와의 이전 협력에 이어진다. 이 이니셔티브는 자가면역 질환 관리에서 충족되지 않은 요구를 해결하기 위해 보다 효과적이고 안전하며 개인화된 치료 옵션을 개발하는 것을 목표로 한다.
Flagship Pioneering a annoncé une nouvelle collaboration entre son unité de découverte de médicaments Pioneering Medicines et Pfizer pour découvrir de nouveaux inhibiteurs potentiels pour le traitement des maladies auto-immunes. Ce partenariat utilisera Logica, une plateforme développée par Valo Health et Charles River qui combine une technologie alimentée par l'IA avec une expertise en découverte de médicaments pour traduire des connaissances biologiques en petites molécules optimisées.
Ceci marque le sixième accord dans le cadre du partenariat stratégique entre Flagship Pioneering et Pfizer, après des collaborations précédentes avec ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics et Ampersand Biomedicines. L'initiative vise à répondre aux besoins non satisfaits dans la gestion des maladies auto-immunes en développant des options de traitement plus efficaces, plus sûres et personnalisées.
Flagship Pioneering hat eine neue Zusammenarbeit zwischen seiner Arzneimittelforschungsabteilung Pioneering Medicines und Pfizer bekannt gegeben, um potenzielle neue Inhibitoren für die Behandlung von Autoimmunerkrankungen zu entdecken. Die Partnerschaft wird Logica nutzen, eine von Valo Health und Charles River entwickelte Plattform, die KI-gestützte Technologie mit Fachwissen in der Arzneimittelforschung kombiniert, um biologische Erkenntnisse in optimierte kleine Moleküle zu übersetzen.
Dies markiert das sechste Abkommen im Rahmen der strategischen Partnerschaft zwischen Flagship Pioneering und Pfizer, nach früheren Kooperationen mit ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics und Ampersand Biomedicines. Die Initiative zielt darauf ab, die unerfüllten Bedürfnisse im Management von Autoimmunerkrankungen zu adressieren, indem effektivere, sicherere und personalisierte Behandlungsoptionen entwickelt werden.
- Strategic partnership with major pharmaceutical company Pfizer
- Access to advanced AI-powered drug discovery platform Logica
- Expansion into high-demand autoimmune disease market
- Early-stage drug discovery with no guaranteed success
- Timeline to potential commercialization not specified
Collaboration leverages Logica, a platform offering from Valo Health and Charles River that directly translates biological insights into optimized small molecules
Sixth agreement signed under strategic partnership between Flagship Pioneering and Pfizer to accelerate discovery of innovative compounds that may become medicines targeting unmet needs
The collaboration will engage Charles River to utilize Logica®, a unique platform offering from Valo Health, a Flagship-founded company, to identify advanceable small molecule leads. Logica translates biological insights into optimized preclinical assets by leveraging Valo Health's AI-powered Opal Computational Platform and Charles River's leading drug discovery expertise.
"Autoimmune diseases impose a substantial health burden on patients, and ongoing unmet need in the management of these conditions is driving a strong demand for more effective, safer and more personalized treatment options," said Paul Biondi, President, Pioneering Medicines, and Managing Partner, Flagship Pioneering. "Through the power of our unique partnership model with Pfizer, we will leverage Logica to help address this gap with a promising novel approach to identifying disease-modifying candidate molecules that could positively impact the current treatment landscape for these complex and diverse conditions."
This agreement represents the sixth collaboration signed under the broader strategic partnership between Flagship Pioneering and Pfizer to create a new pipeline of innovative assets, following programs announced with Flagship companies ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics, and Ampersand Biomedicines.
"We are excited to bring the power of the Logica platform – powered by Valo and Charles River – to discover potential investigational therapies for patients suffering from autoimmune diseases," said Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River. "Logica's proprietary AI small molecule drug discovery platform is revolutionizing the drug discovery process, and we look forward to working with the joint team at Pioneering Medicines and Pfizer to accelerate understanding of the molecular pathways involved in these diseases to develop more targeted and effective therapies for patients."
About Flagship Pioneering and Pioneering Medicines
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than
Pioneering Medicines, Flagship Pioneering's in house drug development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship's innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship's multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts which are then advanced jointly with Flagship's bioplatform companies. Within Flagship's Innovation Supply Chain partnerships, Pioneering Medicines works with external collaborators to apply its unique approach to partners' R&D priorities. These partnerships are highly co-creative strategic alliances that accelerate therapeutic innovation by bringing together partners spanning the full spectrum of drug discovery, development, and production.
Media Contact:
press@flagshippioneering.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-announces-agreement-between-pioneering-medicines-and-pfizer-to-discover-potential-novel-selective-inhibitors-for-autoimmune-disease-302415941.html
SOURCE Flagship Pioneering
FAQ
What is the purpose of the Flagship Pioneering and Pfizer collaboration for FHTX?
How many agreements has FHTX signed with Pfizer under their strategic partnership?
Which companies are involved in the Logica platform being used in this FHTX collaboration?
What therapeutic area is targeted in this FHTX-Pfizer collaboration?
